Track and trace has apparently been trashed, at least for now. Unable to agree on details between what the FDA was seeking and what the industry was willing to sign off on, the plan to finally create a nationwide system that could identify and follow individual drugs through a serpentine supply chain got left on the negotiating floor, Reuters reports, citing anonymous sources. The plan was to be a part of the FDA user fee reauthorization bill that Congress has been reconciling, one of the few pieces of legislation with bipartisan support in this tense pre-election session. The staffer said some lawmakers may try to introduce the measure as a stand-alone bill later this year. But the legislation may have a hard time making it through a divided Congress. Story | More